These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 29062552

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH, Lin D, Xu L, Wang Q, Hu HH, Xu HP, He ZY.
    Oncotarget; 2017 Jan 10; 8(2):3412-3421. PubMed ID: 27926500
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
    Mazières J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban T, Moro-Sibilot D, Dansin E, Chouaid C, Wislez M, Diebold J, Felip E, Rouquette I, Milia JD, Gautschi O.
    J Clin Oncol; 2013 Jun 01; 31(16):1997-2003. PubMed ID: 23610105
    [Abstract] [Full Text] [Related]

  • 6. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine MP, Westeel V, Longchampt E, Wislez M, Coudert B, Daniel C, Chetaille B, Michiels S, Blons H, Solassol J, De Fraipont F, Foucher P, Urban T, Lacroix L, Poulot V, Quoix E, Antoine M, Danton G, Morin F, Chouaid C, Pignon JP.
    J Thorac Oncol; 2012 Oct 01; 7(10):1490-502. PubMed ID: 22982650
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH, Lee JY, Sun JM, Ahn JS, Park K, Ahn MJ.
    J Thorac Oncol; 2014 Apr 01; 9(4):506-11. PubMed ID: 24736073
    [Abstract] [Full Text] [Related]

  • 9. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
    Qiu B, Liang Y, Li Q, Liu G, Wang F, Chen Z, Liu M, Zhao M, Liu H.
    Clin Lung Cancer; 2017 Nov 01; 18(6):e369-e373. PubMed ID: 28465010
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Clinical outcomes in patients with advanced epidermal growth factor receptor-mutated non-small-cell lung cancer in South Western Sydney Local Health District.
    Ding PN, Roberts TL, Chua W, Becker TM, Descallar J, Yip PY, Bray V.
    Intern Med J; 2017 Dec 01; 47(12):1405-1411. PubMed ID: 28742280
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
    Labbé C, Cabanero M, Korpanty GJ, Tomasini P, Doherty MK, Mascaux C, Jao K, Pitcher B, Wang R, Pintilie M, Leighl NB, Feld R, Liu G, Bradbury PA, Kamel-Reid S, Tsao MS, Shepherd FA.
    Lung Cancer; 2017 Sep 01; 111():23-29. PubMed ID: 28838393
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinicopathological characteristics and prognosis of non-small cell lung cancer in Algeria: a single-center retrospective study.
    Lahmadi M, Beddar L, Ketit S, Makhbouche T, Laouar N, Filali T.
    BMC Cancer; 2024 Aug 02; 24(1):946. PubMed ID: 39095812
    [Abstract] [Full Text] [Related]

  • 18. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
    Izar B, Sequist L, Lee M, Muzikansky A, Heist R, Iafrate J, Dias-Santagata D, Mathisen D, Lanuti M.
    Ann Thorac Surg; 2013 Sep 02; 96(3):962-8. PubMed ID: 23932319
    [Abstract] [Full Text] [Related]

  • 19. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors.
    Lee SJ, Lee JI, Nam DH, Ahn YC, Han JH, Sun JM, Ahn JS, Park K, Ahn MJ.
    J Thorac Oncol; 2013 Feb 02; 8(2):185-91. PubMed ID: 23328548
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.